An abstract on Xeltis clinical data has been shortlisted as one of five finalists at the EACTS Techno-College Innovation Award. Professor Tomasz Mroczek from the Children’s University Hospital, Krakow, Poland will present 1-year Xeltis data on the “First clinical experience [...]
Initial in vivo experience on Xeltis’ restorative aortic valve will feature as one of the highest peer-reviewed oral abstracts of TCT 2018. Professor Christian Spaulding, Chief, Interventional Cardiology, European Hospital Georges Pompidou, Paris (F), will present long-term pre-clinical on Xeltis’ [...]
Preclinical data on Xeltis’ restorative heart valve technology will feature at the 16th International Society of Applied Cardiovascular Biology (ISACB) Biennial meeting. Professor Frederick J. Schoen from Harvard Medical School will present 1-year preclinical data outlining the capability of Xeltis [...]
The Children’s Hospital Colorado has joined other prominent U.S. pediatric centers in the Xplore-2 clinical research study, the first medical center in the Mountain States to take part in the trial. The medical institutions already enrolling patients as part of the [...]
The potential for Xeltis’ restorative technology in aortic valves will be showcased at the International Society for Minimally Invasive Cardiothoracic Surgery meeting in Vancouver on June 13-16. Doctor Gregory Fontana, CardioVascular Institute Los Robles Hospital, Thousand Oaks, California, will [...]
Dr Gregory Fontana, National Medical Director for Cardiovascular Research, at the Hospital Corporation of America, Nashville, Tennessee, (U.S.), will present data on Xeltis’ restorative aortic valves at the Heart Valve Society meeting in New York on April 12-14, 2018. In [...]
Positive Xeltis data from two clinical trials on Endogenous Tissue Restoration (ETR) applications show encouraging progression for the RestoreX technology. The data have been shared at the 7th World Congress of Pediatric Cardiology & Cardiac Surgery (WCPCCS) in Barcelona, Spain. [...]
Xeltis’ long-standing academic research partner, the University of Technology Eindhoven (TU/e), has been awarded with seven Vidi grants for their top-quality research. Of the seven grants, three have been awarded to TU/e Institute for Complex Molecular Systems (ICMS), which is [...]
Industry discussions turn to Xeltis’ disruptive potential in heart valve replacement from the front cover of MedTech Strategist’s latest issue. In an extensive interview with Xeltis’ CEO Laurent Grandidier and COO Boris Warnack, editor David Cassak explores the opportunities for [...]
Xeltis’ Eindhoven facilities have been recognized as complying with the requirements of ISO 13485:2003 and EN ISO 13485:2012 for the design, development and manufacture of sterile bioabsorbable cardiovascular implants. The extended certification demonstrates Xeltis’ commitment to upholding the vigorous manufacturing [...]
